SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Medicenna Reports MDNA209 Preclinical Survival Results in Autoimmune Models

The company said its engineered Superkine blocked CD122 and extended median survival by up to fourfold in aggressive mouse models. It is designed to inhibit IL-2 and IL-15 signalling.

MDNA

Related stories